Dicerna to Present at September Investor Conferences
September 06 2016 - 4:05PM
Business Wire
Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer
of investigational RNA interference (RNAi) therapeutics, today
announced that Douglas M. Fambrough, Ph.D., president and chief
executive officer, will present at the following investor
conferences in September.
- Rodman & Renshaw 18th Annual Global
Investment Conference on Tuesday, September 13, 2016 at 2:35-3:00
p.m. ET at the Lotte New York Palace Hotel in New York City.
- Leerink Partners Rare Disease and
Immuno-Oncology Roundtable Series on Wednesday, September 28, 2016
at 10:35-11:00 a.m. ET at the Lotte New York Palace Hotel in New
York City.
A live webcast of each presentation can be accessed on the
Investors & Media section of the Dicerna website at
www.dicerna.com. An archived replay of the webcasts will be
available on the Company’s website after each conference.
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., is an RNA interference-based
biopharmaceutical company focused on the discovery and development
of innovative treatments for rare, inherited diseases involving the
liver, for other therapeutic areas in which the liver plays a key
role, and for cancers that are genetically defined. The Company is
using its proprietary RNA interference (RNAi) technology platform
to build a broad pipeline in these therapeutic areas. In many
cases, Dicerna is pursuing targets that have historically been
difficult to inhibit using conventional approaches, but where
connections between targets and diseases are well understood and
documented. The Company intends to discover, develop and
commercialize these novel therapeutics either on its own or in
collaboration with pharmaceutical partners. For more information,
please visit www.dicerna.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160906006382/en/
Investors:Rx Communications GroupMelody Carey,
917-322-2571mcarey@rxir.comorMedia:SmithSolveAlex Van Rees,
973-442-1555, ext. 111alex.vanrees@smithsolve.com
Dicerna Pharmaceuticals (NASDAQ:DRNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dicerna Pharmaceuticals (NASDAQ:DRNA)
Historical Stock Chart
From Apr 2023 to Apr 2024